NEW YORK (TheStreet) -- Shares of Supernus Pharmaceuticals (SUPN) - Get Report were gaining 11.6% to $11.08 on heavy trading volume Wednesday after the drug company beat analysts' estimates for earnings and revenue in the fourth quarter.

Supernus Pharmaceuticals reported earnings of 10 cents a share for the fourth quarter, beating analysts' estimates of a loss of 12 cents a share. Revenue grew 198.2% year over year to $30.8 million for the quarter, above analysts' estimates of $24.36 million.

President and CEO Jack Khattar said, "During our November earnings call, we reiterated that the Company would become cash flow positive by the end of the fourth quarter. Not only was the Company cash flow positive for the month of December, but it was also significantly cash flow positive for the entire fourth quarter. In addition, net product revenue of approximately $30 million for the fourth quarter substantially exceeded our guidance of $24 million to $26 million."

About 2.6 million shares of Supernus Pharmaceuticals were traded by 11:54 a.m. Wednesday, above the average trading volume of about 334,000 shares a day.

TheStreet Ratings team rates SUPERNUS PHARMACEUTICALS INC as a Hold with a ratings score of C. TheStreet Ratings Team has this to say about their recommendation:

"We rate SUPERNUS PHARMACEUTICALS INC (SUPN) a HOLD. The primary factors that have impacted our rating are mixed -- some indicating strength, some showing weaknesses, with little evidence to justify the expectation of either a positive or negative performance for this stock relative to most other stocks. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and compelling growth in net income. However, as a counter to these strengths, we find that the stock has had a generally disappointing performance in the past year."

You can view the full analysis from the report here: SUPN Ratings Report

SUPN data by YCharts